Recommended Principles and Practice of #IMPOCUS - @SonoInternist now in press - Medical Clinics of North America - available for free at this link until Oct 22: https://t.co/8ydHIMNSWE

W/ @jerrysalame79's collaboration & @IM_POCUS's leadership, "Basic Cardiac Point-of-Care Ultrasound and Its Clinical Applications" is out! It emphasizes implications of clinical interpretation and applications d/t probe manipulation issues and limitations of various cardiac

It's been an honour to be part of this project Thanks to @IM_POCUS for the invitation and impulse and @chrissyschutzer for her generosity and wisdom @yaletung @GTECOSEMI @SonoSamMD @Sociedad_SEMI @drmiguelmarcos @juliomayol @mendez_bailon @JoseMPorcel @javiteigell

Someone actually did an RCT of the DDAVP Clamp vs rescue use of DDAVP! Seems underpowered so the lack of statistical significance for the primary outcome of overcorrection is a bit suss but faster correction at 48 hours for reactive. https://t.co/zAoYrmfBsZ

Implementation Scientists and @AriadneLabs @HarvardChanSPH This resource put together by @KClaraPark and colleagues @HarvardCatalyst is outstanding. 🔥 1. Theories, Models, Frameworks 2. Research Design 3. Implementation Strategies 4. Outcomes https://t.co/5EUWt6z8mk

#echofirst #CardioTwitter Middle aged male with MR and evidence of pulmonary hypertension. 🔻 end-systolic D-sign = RV-pressure overload 🔻 mid-systolic notch in RVOT PW Doppler signal 🔻 shortened pulmonary acceleration time (PAT) < 100 ms https://t.co/4heiy45VNE

What is the key to safe and effective POCUS? ⁦@JaneveDesy⁩ chiara cogliati TY ⁦@IM_POCUS⁩

Our #IMPOCUS learners got treated to visiting professor Dr Gerard Salame’s phenomenal talk on Cardiac Optimization today. Thank you!!! Sorry I was out of commission. Maybe we’ll just have to have you come back :)

🚨 Join top experts for the 2025 Vasculitis & Polymyalgia Rheumatica Update! Join us on March 28-29, 2025 to discuss new treatments, diagnostic tools & patient outcomes. #RheumatologyCME #Vasculitis Register Today! https://t.co/qPoSVzxpDO

Need a power/sample size calculation for a study or upcoming grant? Led by @emil_hs, we built a simple, free, and pain-free (!) shiny app. feedback welcome plz share with interested parties. check it out: https://t.co/LpRB08Y7vA 🦾🤓 @sholzberg @kieranrcampbell @JeffsLianne

Looking with interest at this French study results in ICM for my pleasure ;) 1) JV was the most representative compared with femoral and subclavian vein 2) CRBSI per 1000 CVC days 0.7 for JV and FV and 0.6 for SV 3) In other words, NO DIFFERENCE (p 0.248)

🩺 Clinicians: https://t.co/dTG5GTzHKN provides comprehensive guidance for working up the etiology of cirrhosis, including initial lab investigations for conditions like PBC, PSC, and more. A must-have resource for accurate diagnosis and management. https://t.co/Lk90AO8zIX

🫀ANOTHER NEW GUIDELINE🫀 We have just released "Recommendations for Cardiac Point-of-Care Ultrasound Nomenclature." Read it here: https://t.co/6H8s9hAw97 #ASEGuidelines #POCUS #CardioX

Looking for more detail on Doppler in #POCUS? Principles of Doppler Ultrasonography and Basic Applications for the Clinician - Medical Clinics https://t.co/LU0asSp1hs @Buchanan_MD @GoffiAlberto @UAlberta_ICU @UAlberta_FoMD @IM_POCUS

Graphic representation of #Echofirst parameters 4assessment of #RV pressure overload from #PE guidelines 1. 🔼RV size 2.Dilated RV 3. Flat IVS 4. Dilated IVC 5. 60/60 sign Pulmo. ET <60ms PASP<60 mmHg 6. RV thrombus 7. TAPSE <16 8. S' velocity <9.5cm/s #ESCCongress

"Words matter:" an 8 society consensus document on nomenclature for cardiac #POCUS. Now we all speak the same language. Led by @ASE360 Recommendations for Cardiac Point-of-Care Ultrasound Nomenclature - Journal of the American Society of Echocardiography

Your source for #echofirst imaging in #HCM is @ASE360

New Vascular and aortic management guidelines fresh off the press #ESCCongress2024 @escardio @VDelgadoGarcia @GenTACAlliance @MarfanFdn @ASE360 @ACCinTouch @AHAScience @Aortahub

RESHAPE-HF trial: Among patients with at least moderate functional mitral regurgitation, transcatheter valve repair led to a lower rate of heart failure events during 24 months and better health status at 12 months than medical therapy alone. https://t.co/2eaS8ceLPv #ESCardio

Presented at #ESCardio: Among patients with transthyretin amyloidosis with cardiomyopathy, the risk of death from any cause and recurrent cardiovascular events was lower with vutrisiran treatment than with placebo. Full HELIOS-B trial results: https://t.co/3MZy3lLznK